Peer-reviewed veterinary case report
Isotretinoin treatment results for dogs with skin lymphoma
By Ramos, Sofia Chichorro et al.·Published in Veterinary dermatology·2022·North Downs Specialist Referrals, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Isotretinoin treatment of 12 dogs with epitheliotropic lymphoma.
- Species:
- dog
Plain-English summary
Twelve dogs with a rare skin cancer called epitheliotropic lymphoma were treated with isotretinoin, a medication often used for severe skin conditions. Out of these dogs, four had all their skin lesions completely resolve, while three others showed noticeable improvement. Unfortunately, two dogs did not see any change, and three had worsening symptoms despite the treatment. Some dogs experienced mild side effects, but these were temporary and did not impact their quality of life. Overall, isotretinoin proved to be a safe and effective option for managing this type of cancer in dogs.
People also search for: dog skin cancer treatment · isotretinoin for dogs · epitheliotropic lymphoma in dogs · dog cancer skin lesions · side effects of isotretinoin in dogs
Abstract
BACKGROUND: Epitheliotropic lymphoma is an uncommon cutaneous malignancy of T lymphocytes. Limited information is available regarding the treatment and outcome of dogs with this disease. OBJECTIVES: To evaluate the treatment outcome and toxicity profile of isotretinoin in dogs with epitheliotropic lymphoma. ANIMALS: Twelve dogs with a diagnosis of epitheliotropic lymphoma were included. MATERIALS AND METHODS: A medical database was searched for dogs diagnosed with epitheliotropic lymphoma and treated with isotretinoin between 2010 and 2021. Diagnosis, treatment details and tumour response were recorded for 12 dogs. RESULTS: All lesions resolved in four of 12 (33%) treated dogs. Lesions visibly improved in a further three dogs, giving a response rate of 58%. Two dogs' lesions remained unchanged and three progressed despite therapy. Adverse effects occurred in three dogs (25%), all of which were rapidly resolving or not affecting quality of life. CONCLUSION: Isotretinoin treatment was a well-tolerated and effective treatment for canine epitheliotropic lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35637167/